Small-cap stocks largely slung under the major indices Wednesday, and one of the worst-performing names was XTL Biopharmaceuticals ( XTLB).

The Valley Cottage, N.Y., firm plunged 17.2% to $2.92 on news it had suspended development on its XTL-2125 compound, a proposed treatment for hepatitis C, after an early-phase study yielded statistically insignificant results in drug efficacy.

Angeion ( ANGN), which makes noninvasive cardio-respiratory diagnostic systems, forecast reduced profitability for the fiscal third and fourth quarters vs. last year due to dwindling revenue from its largest clinical-research customer. Despite positive results for the most recent quarter, shares of the St. Paul, Minn., company lost 13.1%, or $1.42, to $9.42.

Meanwhile Georgia-based Matria Healthcare ( MATR) said it will end its short-lived relationship with insurer Wellmark Blue Cross & Blue Shield at year-end. The collaboration, which began in only February, had been originally slated to last for 10 years. Shares slid 6.3% to $29.42.

Matria helped take down with it both the Russell 2000 and the S&P SmallCap 600, which respectively gave up 0.9% and 1.1%.

Apparel maker Oxford Industries ( OXM), also a member of both indices, sank 3.5% to $42.66 after cutting its outlook for the fiscal fourth quarter and full year. Adjusted earnings for the quarter, now predicted at 96 cents to $1.01 a share, would miss Thomson Financial's estimates by at least 2 cents. Prior guidance had called for $1 to $1.07 a share.

If you liked this article you might like

Lackluster Finish for U.S. Stocks

Lackluster Finish for U.S. Stocks

Stocks Continue to Waver at the Flat Line

Stocks Continue to Waver at the Flat Line

Oil Slides as Stocks Post a Mixed Showing

Oil Slides as Stocks Post a Mixed Showing

Stocks Flutter Near the Flat Line

Stocks Flutter Near the Flat Line

Wall Street Falls Amid Inflation Talk

Wall Street Falls Amid Inflation Talk